Cautious Hold Rating for CureVac Amid Uncertain Revenue Projections

In a report released on May 20, Mani Foroohar from Leerink Partners reiterated a Hold rating on CureVac (CVAC – Research Report), with a price target of $3.00.

Mani Foroohar’s rating is based on a combination of factors that include the recent updates to the CureVac model, which involved adjusting revenue projections due to the uncertain timing of milestone recognitions from their partner, GSK. Despite these adjustments, the price target for CureVac remains unchanged, indicating a balanced outlook on the stock’s potential performance.
Given these considerations, the Hold rating suggests that while there are no immediate catalysts for significant growth, there is also no pressing reason to sell the stock. This reflects a cautious approach, acknowledging both the potential and the uncertainties surrounding CureVac’s future revenue streams.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVAC in relation to earlier this year.